EGFR and head and neck squamous cell carcinoma: As HNSCC is a highly heterogeneous disease and targeted EGFR monotherapy has produced moderate results in treatment efficacy, and in some cases has even led to therapeutic resistance [196,216], future studies are expected to concentrate on the development of combination therapies.